Test Price
1,200 AED✅ Home Collection Available
BCR-ABL1 Quantitative (p210, p190, p230) in UAE | 1200 AED | DHA Guidelines
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-accredited Real-Time PCR (qPCR) with electronic probe detection.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Telephonic post-test clinical guidance by DHA-licensed physicians to interpret results in the context of your treatment.
- Insurance: Direct Billing Verification – WhatsApp +971 54 548 8731.
Test Overview & Methodology
BCR-ABL1 Quantitative PCR measures fusion transcripts (p210, p190, p230) to monitor treatment response in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test provides precise, internationally calibrated results essential for clinical decision-making.
| Feature | Our Test (Real-Time qPCR) | Closest Alternative (FISH/Cytogenetics) |
|---|---|---|
| Methodology | Quantitative Real-Time PCR with international scale (IS) standardization | Fluorescence in situ hybridization (FISH) or karyotyping |
| Sensitivity | Detects 1 CML cell in 10⁴–10⁵ normal cells (deep molecular response) | Usually 1 in 200–500 cells (limited sensitivity) |
| Turnaround Time | 3–4 working days | 7–14 days |
| Dynamic Monitoring | Quantitative trend for MRD monitoring | Qualitative / semi-quantitative only |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that the BCR-ABL1 quantitative result is a cornerstone of monitoring in CML. However, it must always be interpreted alongside clinical history and prior treatment milestones. A single negative result does not signify cure; consistent molecular monitoring is essential.” —Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Medication Advisory
⚠️ Do not discontinue or modify your prescribed tyrosine kinase inhibitor (TKI) therapy based solely on this test result without consulting your treating oncologist.
Exclusion Criteria & Safety Precautions
- Exclusion Criteria: Active, uncontrolled infection; recent major surgery (within 2 weeks) may require rescheduling home collection to guarantee sample integrity.
- Prescription Mandate: A valid DHA-registered physician’s prescription is required. Exemptions may apply for pre‑travel screening, pregnancy or pre‑surgery assessment in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If you experience sudden worsening fatigue, unexplained bruising/bleeding, fever >38.5°C or splenic pain, seek immediate medical attention—do not wait for results.
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of quantifying BCR-ABL1 p210, p190, and p230?
These fusion transcripts are quantified by Real-Time PCR to monitor minimal residual disease and early molecular response in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The test is internationally standardized for consistent results.
2. How do I prepare for the home blood collection?
A valid doctor’s prescription is required. No fasting is necessary. Please inform the phlebotomist of all current medications and any recent fever to ensure sample quality.
3. How soon will I receive the result and what does a “molecular response” mean?
Results are typically available within 3–4 working days. A major molecular response (MMR) means BCR-ABL1 ≤0.1% on the International Scale, a key milestone in CML management. Your physician can explain the clinical significance.
UAE Regulatory & Data Privacy Adherence
All patient data is handled in strict compliance with the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | BCR-ABL1 Quantitative (p210, p190, p230) |
| Price (AED) | 1200 |
| Turnaround Time | 3–4 working days |
| Sample Type / Matrix | Peripheral blood |
| Methodology Used | Real-Time PCR (qPCR) with International Scale standardization |
| ICD-10-CM Code | C92.1 (Chronic myeloid leukemia, BCR/ABL-positive) |
| LOINC Code | 34815-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians